We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a ...

Supernus Pharmaceuticals got a positive adjustment to its Relative Strength (RS) Rating, from 67 to 81. Please watch the video at Investors.com - Do Your Stocks Meet This Key Standard? Here's Why ...

NEW YORK, NY / ACCESS Newswire / April 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...

Supernus has boosted its position in central nervous system therapies with a $400 million deal to acquire Adamas Pharma that will add two approved Parkinson's disease therapies to its stable.

About Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS ...

Supernus Pharma has suffered a blow to its R&D pipeline after a candidate for treatment-resistant depression failed a phase 2b trial, sending its share into a tailspin. The stock was down nearly ...

Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further analysis and discussions on its future.

The Cerebral Palsy market has demonstrated substantial growth in recent years, driven by increasing awareness, improved ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...